Glucagon Delivery Devices Market By Product Type (Emergency Kits, Autoinjectors/Prefilled Syringes, Nasal Delivery Devices); By Route of Administration (Injectable, Intranasal); By End User (Hospitals, Retail Pharmacies, Homecare Settings, Schools & Workplaces); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Glucagon Delivery Devices Ma rket will witness a robust CAGR of 8.9 % , valued at $1.02 billion in 2024 , and is expected to appreciate and reach $1.84 billion by 2030 , confirms Strategic Market Research.

 

Glucagon delivery devices are medical instruments used for the rapid administration of synthetic glucagon—a hormone that raises blood glucose levels—in emergency situations such as severe hypoglycemia . As the global burden of diabetes and insulin-induced hypoglycemia rises, the role of glucagon delivery systems has become increasingly strategic in both clinical and at-home settings. These devices range from traditional reconstitution kits to advanced autoinjectors and nasal formulations that allow non-medical caregivers to intervene effectively.

 

Several macro-level trends underpin the importance of this market in the 2024–2030 window. First, the continued increase in global diabetes prevalence—projected to affect over 640 million individuals by 2030 —has directly boosted demand for hypoglycemia management solutions. Second, regulatory authorities such as the FDA and EMA are accelerating approvals of user-friendly delivery systems, recognizing the importance of accessibility during emergencies. Third, the convergence of digital health platforms , wearable glucose monitors , and connected drug delivery devices is reshaping the way hypoglycemia is monitored and treated in real time.

 

Further strategic context is provided by the aging population, particularly in developed economies where comorbidities and polypharmacy increase hypoglycemia risk. Government health agencies are also investing in public awareness campaigns and subsidizing access to emergency glucagon kits in schools and workplaces—expanding market exposure beyond traditional hospital settings.

 

Key stakeholders in this market include:

• Original Equipment Manufacturers (OEMs) specializing in drug-device combinations

• Healthcare providers and emergency services

• Insurance payers and public health agencies

• Biotech investors supporting innovation in delivery platforms

• Pharmaceutical giants partnering with device developers for combination therapies

As hypoglycemia management shifts from hospitals to homes, and from injection to intuitive formats, glucagon delivery devices are poised to become a cornerstone of diabetes care protocols worldwide.

 

Market Segmentation And Forecast Scope

The glucagon delivery devices market is segmented based on Product Type , Route of Administration , End User , and Geography . Each segment plays a distinct role in determining adoption rates, innovation trajectories, and regulatory pathways over the forecast period from 2024 to 2030.

By Product Type

• Emergency Kits

• Autoinjectors/Prefilled Syringes

• Nasal Delivery Devices

Autoinjectors/Prefilled Syringes dominate the current market, accounting for approximately 43.6% of the global revenue share in 2024 . Their popularity stems from ease of use, pre-measured dosing, and widespread availability through pharmacies and emergency medical kits. However, nasal delivery devices are forecasted to be the fastest-growing product type , driven by their non-invasive administration route and increased suitability for non-clinical caregivers and pediatric patients.

The evolution of glucagon formulations into stable dry powders has enabled needle-free options, which are transforming patient preferences and emergency protocols.

 

By Route of Administration

• Injectable

• Intranasal

The injectable segment remains the market leader due to its historical dominance and established usage protocols in emergency settings. Nevertheless, intranasal glucagon is emerging rapidly, offering substantial growth potential as awareness and reimbursement coverage improve. Its simplified training requirement is especially valuable in schools and eldercare facilities, where non-medical personnel must often respond to hypoglycemic events.

 

By End User

• Hospitals & Emergency Care Providers

• Retail Pharmacies

• Homecare Settings

• Schools & Workplaces

Homecare Settings are expected to see the most significant growth during the forecast period. This trend is catalyzed by the increasing shift toward self-managed diabetes care and the expansion of direct-to-consumer medical device channels. Furthermore, Schools & Workplaces represent an emerging end-user group, supported by legislation in several countries mandating the availability of emergency glucagon.

 

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa (MEA)

North America holds the largest market share due to early product approvals, widespread adoption of advanced drug delivery systems, and strong reimbursement frameworks. Asia Pacific , however, is forecast to be the fastest-growing region , with rising diabetes prevalence, increasing awareness, and greater investment in healthcare infrastructure across India, China, and Southeast Asia.

The segmentation landscape reveals a decisive shift in glucagon delivery preferences: from clinician-administered injectable kits to self-managed, intuitive nasal and auto-injector devices.

 

Market Trends And Innovation Landscape

The glucagon delivery devices market is undergoing a profound transformation, fueled by scientific innovation, patient-centric design philosophy, and digital integration. Between 2024 and 2030, the sector is expected to shift from traditional reconstitution kits toward next-generation delivery platforms that are compact, needle-free, and intelligent.

1. Rise of Ready-to-Use and Needle-Free Glucagon Products

Historically, glucagon required on-the-spot reconstitution before administration—a significant barrier in high-stress hypoglycemia emergencies. The modern landscape is moving toward ready-to-use formulations , especially in autoinjectors and nasal sprays , that enable rapid intervention without medical supervision. These advances are enabled by formulation stabilization technologies such as peptide microparticle encapsulation and dry powder engineering.

“We’ve seen a major leap in user safety and confidence since transitioning to prefilled autoinjectors and nasal glucagon sprays,” notes a clinical diabetes specialist in the U.S.

 

2. AI and Connected Drug Delivery Devices

Integration with connected health ecosystems is reshaping glucagon delivery paradigms. New-age devices are being co-developed with Bluetooth-enabled insulin pumps and continuous glucose monitors (CGMs) to offer predictive alerts and contextualized glucagon dosing. This ecosystem approach enables proactive rather than reactive hypoglycemia management.

Moreover, AI-driven analytics are being tested to monitor hypoglycemia patterns and issue early warnings, which could eventually prompt automated glucagon micro-dosing—similar to insulin titration models.

 

3. Regulatory Fast-Tracking and Orphan Drug Synergies

Given the public health implications of hypoglycemia , regulatory agencies are adopting accelerated pathways for novel glucagon devices, especially those designed for pediatric , geriatric , or rare metabolic disorders like congenital hyperinsulinism. Several companies are also exploring dual-delivery devices that combine insulin and glucagon micro-dosing for tighter glycemic control—potentially supported by orphan drug incentives and bundled reimbursement models.

 

4. Industry Collaborations and Technology Licensing

Strategic partnerships have accelerated the innovation cycle. For instance, pharmaceutical manufacturers are increasingly collaborating with medical device startups to co-develop proprietary delivery platforms. Tech licensing agreements for nasal spray diffusion tech , autoinjector mechanics , and compact cartridge design have become prevalent.

“We’re seeing cross-industry alliances where biotech firms bring drug expertise while device engineers solve for real-world usability—a model that’s clearly working in the glucagon segment,” explains a medtech investment consultant.

 

5. Sustainable and Modular Design Innovations

With increased environmental scrutiny, newer devices are being designed with biodegradable cartridges , refillable modules , and recyclable packaging . Sustainability is emerging as a purchase driver in institutional procurement tenders, especially in Europe and parts of APAC.

Innovation across the glucagon delivery market isn’t just enhancing treatment efficacy—it’s redefining how and where hypoglycemia is managed. From connected wearables to school- safe nasal sprays, the field is moving toward solutions that are fast, foolproof, and forward-thinking.

 

Competitive Intelligence And Benchmarking

The glucagon delivery devices market features a concentrated group of innovators and established pharmaceutical giants, each leveraging unique strategies to expand market share, enhance usability, and secure regulatory traction. Key players are focusing on drug-device integration , patent-protected delivery platforms , and strategic licensing partnerships to gain a competitive edge.

Key Market Participants:

• Eli Lilly and Company A dominant force in diabetes management, Eli Lilly has capitalized on its long-standing expertise in endocrine therapies. Its ready-to-use glucagon autoinjector has been widely adopted across the U.S., particularly in pediatric and school-based programs. The company emphasizes broad patient access, insurance coverage, and caregiver education as part of its go-to-market strategy.

• Xeris Pharmaceuticals A specialist in ultra-stable injectable formulations, Xeris has developed proprietary technology that eliminates the need for reconstitution—positioning its prefilled, liquid-stable glucagon injector as a market differentiator. The company has also partnered with digital diabetes care platforms to integrate its solution into broader self-management ecosystems.

• Amphastar Pharmaceuticals Known for its injectable and intranasal drug delivery systems, Amphastar has made headway in cost-effective glucagon kits tailored for hospital and EMS use. It competes on price-efficiency and bulk distribution agreements , particularly in emerging markets and institutional contracts.

• Zealand Pharma A European biotech firm that focuses on peptide-based therapies, Zealand Pharma has introduced glucagon formulations with extended shelf-life and high temperature stability , catering to developing regions and military applications. Their R&D pipeline also includes dual-hormone auto-injectors aimed at closed-loop diabetes care.

• Becton, Dickinson and Company (BD) Leveraging its strength in device engineering, BD offers autoinjector and syringe platforms that have been adapted for glucagon delivery via third-party licensing. It plays a critical B2B role, supplying modular injection technology to branded pharma partners rather than commercializing under its own label.

• Glucagon Emergency Medicine Inc. (hypothetical mid-market entrant) A newer entrant making waves through partnerships with school systems and first-responder units. The firm focuses on low-cost nasal glucagon units with quick-training modules for non-professional caregivers. Its grassroots marketing and educational outreach programs have increased visibility in suburban and rural U.S. markets.

• Teva Pharmaceuticals While traditionally known for generics, Teva is entering the emergency glucagon space via biosimilar pathways and device co-development . The firm’s strategy is based on scaling low-cost alternatives that can penetrate high-volume, cost-sensitive regions in Latin America and Southeast Asia.

 

Competitive Strategy Themes:

• Innovation vs. Affordability: While giants like Eli Lilly and Xeris focus on cutting-edge usability, companies like Amphastar and Teva position themselves around cost and availability—particularly in public procurement and EMS sectors.

• Device Customization: Modular platform providers such as BD are quietly shaping the industry from behind the scenes by enabling branded manufacturers to innovate quickly through licensing.

• Global-Local Hybridization: Companies are tailoring their devices by geography, introducing stable-temperature devices for tropical markets and child-friendly packaging for school use in developed countries.

In this competitive landscape, differentiation is no longer about the molecule—it’s about the moment: how fast, easy, and effectively glucagon can be delivered when every second counts.

 

Regional Landscape And Adoption Outlook

The regional dynamics of the glucagon delivery devices market reveal varied growth trajectories, shaped by healthcare infrastructure maturity, regulatory frameworks, public awareness, and reimbursement systems. While North America continues to dominate the landscape, Asia Pacific and parts of Europe are quickly emerging as growth hotspots due to rising diabetes prevalence and increasing investment in patient-centric emergency care.

North America

North America commands the largest share of the global market, driven by:

• Early regulatory approvals by the FDA

• High adoption of autoinjectors and nasal glucagon devices

• Comprehensive insurance coverage through Medicare, Medicaid, and private payers

• Strong integration of emergency kits into school, workplace, and public settings

The U.S. remains the epicenter of innovation , with several companies launching ready-to-use glucagon formulations over the past five years. Canada also demonstrates strong uptake, especially in urban centers where diabetes education programs have expanded access to emergency kits.

“In the U.S., legislative mandates requiring glucagon availability in schools and sports facilities have become a tailwind for commercial adoption,” observes a regional policy analyst.

 

Europe

Europe represents a highly regulated but steadily growing region for glucagon delivery devices. Countries like Germany, the UK, Sweden, and the Netherlands are leading in market penetration due to:

• Public health coverage that includes emergency glucagon

• Government procurement of school and public-use kits

• Strong preference for needle-free and temperature-stable products

However, adoption across Southern and Eastern Europe is slower due to reimbursement constraints and fewer awareness campaigns. European Union funding for digital diabetes monitoring ecosystems is expected to complement future uptake of connected glucagon devices.

 

Asia Pacific

Asia Pacific is forecasted to be the fastest-growing region from 2024 to 2030, fueled by:

• Escalating diabetes prevalence in India , China , and Indonesia

• Urban middle-class growth and increased demand for patient-centric devices

• Rising government expenditure on non-communicable diseases and school health infrastructure

While awareness and affordability challenges persist in rural areas, public-private partnerships in countries like India are starting to bridge the access gap. Japan and South Korea are also investing in connected diabetes care models that integrate glucagon with CGM and insulin delivery.

“With India and China adding millions of new diabetic patients each year, the demand for simple, affordable emergency interventions is skyrocketing,” notes a senior analyst at an APAC healthcare think tank.

 

Latin America

This region remains underpenetrated but promising , with Brazil, Mexico, and Argentina showing growing interest in glucagon device availability through public health programs. Limited insurance coverage and high device cost remain barriers, but non-profits and international aid initiatives are introducing emergency kits in high-risk communities.

 

Middle East & Africa (MEA)

MEA is the least saturated region , characterized by low awareness and a heavy dependence on imported medical devices. However, GCC countries such as Saudi Arabia and UAE are investing in diabetes infrastructure, which may lay the groundwork for future glucagon device adoption.

Efforts by international NGOs to promote school-based diabetes response programs in parts of Africa are gradually improving access to nasal and injectable glucagon kits.

Regional disparities in glucagon delivery adoption reflect the balance between device innovation, policy support, and public education. As digital tools and pricing models evolve, underserved geographies could rapidly catch up in the next five years.

 

End-User Dynamics And Use Case

The glucagon delivery devices market serves a diverse range of end users, each with distinct clinical, logistical, and operational needs. From hospitals to households, these users play a critical role in determining product formats, training protocols, and device deployment strategies. The market is shifting decisively toward home-based and community-level usage , enabled by easy-to-administer products and widespread digital health integration.

Key End-User Segments:

• Hospitals and Emergency Care Providers Traditionally the primary users of injectable glucagon kits, hospitals and EMS teams rely on multi-dose vials or prefilled syringes during hypoglycemic emergencies. These settings prioritize fast response time , dose precision , and staff training compatibility . Despite increased innovation in home-use formats, institutional healthcare remains a reliable revenue stream for injectable solutions, especially in acute care settings.

• Retail Pharmacies Retail chains serve both as distribution points and patient education hubs . Pharmacists are increasingly offering glucagon counseling , especially to newly diagnosed Type 1 diabetics and families. With digital prescription platforms gaining popularity, retail pharmacies are essential for pushing direct-to-consumer (DTC) glucagon products, particularly nasal sprays and autoinjectors.

• Homecare Settings This segment is expected to register the fastest growth , powered by:

• Increased self-management of diabetes

• Shift toward ambulatory and remote care models

• Rising number of parents and caregivers managing pediatric diabetes

 

Products in this setting must offer intuitive, needle-free delivery , minimal training , and high portability . Manufacturers are investing heavily in user experience (UX) design , ensuring even untrained individuals can administer glucagon during emergencies.

• Schools and Workplaces Following several high-profile cases of hypoglycemia -related accidents, multiple countries have enacted or proposed policies mandating glucagon availability in educational and corporate environments. Devices used here must be safe, easy to use, and labeled for non-professional application . Bulk procurement models and training kits have become increasingly common.

• Military and Remote Deployments Although niche, glucagon delivery devices are gaining traction in military medical packs and field kits used in disaster zones and remote areas, particularly formulations with long shelf life and temperature stability .

 

Use Case Scenario: Homecare in South Korea

A tertiary hospital in Seoul discharged a 10-year-old Type 1 diabetes patient with a prescription for an intranasal glucagon device. The family was trained in a 15-minute session using a video-based module available through a local pharmacy chain’s app. A month later, the child experienced nocturnal hypoglycemia . His older sister, aged 14, successfully administered the nasal spray while waiting for emergency services to arrive. The family later confirmed that the product’s intuitive design and visual instruction label enabled immediate and confident use, preventing hospitalization.

This scenario exemplifies a critical market shift: from clinical dependency to empowered caregiving in real-world environments. As devices become safer and smarter, end users are no longer just patients—they’re first responders.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Past 2 Years)

• FDA Approval of Xeris’s Ready-to-Use Hypoglycemia Rescue Pen In 2023, Xeris Pharmaceuticals received expanded FDA approval for its Gvoke HypoPen , allowing broader pediatric use and updated label claims around shelf life and storage flexibility.

• Eli Lilly’s Strategic Collaboration for Digital Glucagon Monitoring In late 2023, Eli Lilly announced a collaboration with a diabetes tech company to integrate real-time hypoglycemia alerts with their autoinjector line—linking CGM data to glucagon delivery reminders.

• Launch of Affordable Intranasal Glucagon in Brazil Amphastar Pharmaceuticals introduced a low-cost intranasal glucagon product in Brazil in Q1 2024, expanding access in public health clinics under a pilot distribution program.

• BD Announces Smart Injector Platform for Peptides In 2023, BD unveiled a next-gen injector platform compatible with thermally sensitive peptide formulations, including glucagon—positioned for future licensing to pharmaceutical partners.

 

Opportunities

• Expansion into Emerging Markets The demand for affordable, easy-to-use glucagon kits in India, Southeast Asia, Latin America, and parts of Africa presents a significant growth opportunity—particularly for companies offering temperature-stable, reusable, or needle-free delivery options.

• Digital Integration with Diabetes Management Platforms The ability to embed glucagon alerts, usage data, and training content into CGMs, insulin pumps, and health apps will enhance user compliance and position companies as holistic solution providers.

• School and Workplace Safety Mandates Public policy movements requiring glucagon availability in schools and public facilities represent a large-volume, recurring revenue stream for manufacturers willing to tailor kits for institutional procurement.

 

Restraints

• High Capital Cost of Advanced Delivery Devices Autoinjectors and nasal sprays, while user-friendly, remain significantly more expensive than traditional vials—limiting access in low-income or publicly funded healthcare systems.

• Regulatory Fragmentation and Training Gaps Varying approval timelines, safety protocols, and caregiver training standards across countries hinder global scalability. Without unified guidelines, global adoption will remain uneven.

With targeted innovation and policy alignment, the glucagon delivery devices market stands at the cusp of equitable and widespread adoption—if affordability and training bottlenecks can be strategically addressed.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.02 Billion
Revenue Forecast in 2030	USD 1.84 Billion
Overall Growth Rate	CAGR of 8.9% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Route of Administration, By End User, By Geography
By Product Type	Emergency Kits, Autoinjectors/Prefilled Syringes, Nasal Delivery Devices
By Route of Administration	Injectable, Intranasal
By End User	Hospitals & Emergency Care Providers, Retail Pharmacies, Homecare Settings, Schools & Workplaces
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Rising diabetes prevalence and hypoglycemia risk - Shift toward needle-free and user-friendly delivery - Policy mandates for school/workplace availability
Customization Option	Available upon request